全文获取类型
收费全文 | 1465篇 |
免费 | 87篇 |
国内免费 | 116篇 |
专业分类
儿科学 | 64篇 |
妇产科学 | 10篇 |
基础医学 | 164篇 |
口腔科学 | 22篇 |
临床医学 | 199篇 |
内科学 | 406篇 |
皮肤病学 | 48篇 |
神经病学 | 32篇 |
特种医学 | 363篇 |
外国民族医学 | 1篇 |
外科学 | 50篇 |
综合类 | 40篇 |
预防医学 | 56篇 |
眼科学 | 14篇 |
药学 | 98篇 |
中国医学 | 1篇 |
肿瘤学 | 100篇 |
出版年
2023年 | 4篇 |
2022年 | 4篇 |
2021年 | 7篇 |
2020年 | 11篇 |
2019年 | 11篇 |
2018年 | 16篇 |
2017年 | 5篇 |
2016年 | 24篇 |
2015年 | 20篇 |
2014年 | 19篇 |
2013年 | 37篇 |
2012年 | 24篇 |
2011年 | 30篇 |
2010年 | 53篇 |
2009年 | 56篇 |
2008年 | 37篇 |
2007年 | 79篇 |
2006年 | 40篇 |
2005年 | 65篇 |
2004年 | 24篇 |
2003年 | 24篇 |
2002年 | 22篇 |
2001年 | 23篇 |
2000年 | 30篇 |
1999年 | 29篇 |
1998年 | 96篇 |
1997年 | 98篇 |
1996年 | 104篇 |
1995年 | 67篇 |
1994年 | 62篇 |
1993年 | 64篇 |
1992年 | 13篇 |
1991年 | 29篇 |
1990年 | 26篇 |
1989年 | 51篇 |
1988年 | 37篇 |
1987年 | 51篇 |
1986年 | 28篇 |
1985年 | 47篇 |
1984年 | 22篇 |
1983年 | 19篇 |
1982年 | 28篇 |
1981年 | 20篇 |
1980年 | 30篇 |
1979年 | 8篇 |
1978年 | 11篇 |
1977年 | 16篇 |
1976年 | 26篇 |
1975年 | 15篇 |
1967年 | 2篇 |
排序方式: 共有1668条查询结果,搜索用时 15 毫秒
101.
102.
Emphysema in the renal allograft 总被引:1,自引:0,他引:1
Two diabetic patients in whom emphysematous pyelonephritis developed after renal transplantation are described. Clinical recognition of this unusual and serious infection is masked by the effects of immunosuppression. Abdominal radiographic, ultrasound, and computed tomography findings are discussed. The clinical presentation includes urinary tract infection, sepsis, and acute tubular malfunction of the allograft in insulin-dependent diabetics. 相似文献
103.
104.
105.
Snoeck J Van Laethem K Hermans P Van Wijngaerden E Derdelinckx I Schrooten Y van de Vijver DA De Wit S Clumeck N Vandamme AM 《Journal of acquired immune deficiency syndromes (1999)》2004,35(3):279-285
This study documented the HIV-1 subtype distribution in 2 Belgian hospitals and determined predictive demographics for non-B subtypes. Overall, subtype B was the most prevalent subtype in this population, followed by subtypes A and C. Several recombinants were detected, circulating recombinants as well as new ones. We found a rise in non-B subtypes from 0% in 1983 to 57% in 2001. The Cochran-Armitage trend test (P < 0.001) as well as the correlation analysis (R = 0.71, P = 0.0006) was highly significant. Recombinants were also increasing in this patient population from 0% in 1983 to 10% in 2001, with good support from the statistical analyses (trend test P < 0.001; correlation analysis R = 0.67, P = 0.0016). Heterosexual route of infection, black African race, African origin of the virus, and year of diagnosis were predictors for infection with non-B subtypes in multivariate analysis. This analysis indicates that the prevalence of non-B subtypes and recombinants in this patient population is high and increasing. Gathering demographic and sequence information from newly diagnosed patients could be useful to further follow the spread of non-B subtypes in Belgium and Europe, but subtyping based on sequence information still remains the most reliable method. 相似文献
106.
Background
In 2002, the World Health Organization published a health system performance ranking for 191 member countries. The ranking was based on five indicators, with fixed weights common to all countries.Methods
We investigate the feasibility and desirability of using mathematical programming techniques that allow weights to vary across countries to reflect their varying circumstances and objectives.Results
By global distributional measures, scores and ranks are found to be not very sensitive to changes in weights, although differences can be large for individual countries.Conclusions
Building the flexibility of variable weights into calculation of the performance index is a useful way to respond to the debates and criticisms appearing since publication of the ranking. 相似文献107.
Vancomycin and teicoplanin are still the only glycopeptide antibiotics available for use in humans. Emergence of resistance in enterococci and staphylococci has led to restriction of their use to severe infections caused by Gram-positive bacteria for which no other alternative is acceptable (because of resistance or allergy). In parallel, considerable efforts have been made to produce semisynthetic glycopeptides with improved pharmacokinetic and pharmacodynamic properties, and with activity towards resistant strains. Several molecules have now been obtained, helping to better delineate structure-activity relationships. Two are being currently evaluated for skin and soft tissue infections and are in phases II/III. The first, oritavancin (LY333328), is the 4'-chlorobiphenylmethyl derivative of chloroeremomycin, an analogue to vancomycin. It is characterised by: i) a spectrum covering vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA) and to some extent glycopeptide-intermediate S. aureus (GISA); ii) rapid bactericidal activity including against the intracellular forms of enterococci and staphylococci; and iii) a prolonged half-life, allowing for daily administration. The second molecule is dalbavancin (BI397), a derivative of the teicoplanin analogue A40926. Dalbavancin has a spectrum of activity similar to that of oritavancin against vancomycin-sensitive strains, but is not active against VRE. It can be administered once a week, based on its prolonged retention in the organism. Despite these remarkable properties, the use of these potent agents should be restricted to severe infections, as should the older glycopeptides, with an extension towards resistant or poorly sensitive bacteria, to limit the risk of potential selection of resistance. 相似文献
108.
Reliable and comparable analysis of risks to health is key for preventing disease and injury. Causal attribution of morbidity and mortality to risk factors has traditionally been conducted in the context of methodological traditions of individual risk factors, often in a limited number of settings, restricting comparability. 相似文献
109.
Valid, reliable and comparable measures of the health states of individuals and of the health status of populations are critical components of the evidence base for health policy. We need to develop population health measurement strategies that coherently address the relationships between epidemiological measures (such as risk exposures, incidence, and mortality rates) and multi-domain measures of population health status, while ensuring validity and cross-population comparability. 相似文献
110.
Timothy K Tippin Geraldine Hamilton Linda Moore Elizabeth J Beaudet Summer Jolley Thomas A Brodie Robert C Andrews J David Becherer Darryl L McDougald Michael D Gaul Debie J Hoivik Kathy Mellon-Kusibab Jurgen Lehmann Steven Kliewer Steven Novick Ron Laethem Zhiyang Zhao Edward L LeCluyse 《Drug metabolism and disposition》2003,31(7):870-877
A series of N-hydroxyformamide tumor necrosis factor-alpha converting enzyme (TACE)/matrix metalloprotease (MMP) inhibitors were evaluated for their potential to induce human cytochrome P450 3A (CYP3A). Two in vitro assays were used: 1) a cell-based reporter gene assay for activation of the pregnane X receptor (PXR), and 2) a primary "sandwich" culture of human hepatocytes. Approximately 50 TACE/MMP inhibitors were evaluated in the human PXR assay. A range of PXR activation was observed, 0 to 150% of the activation of the known human CYP3A inducer rifampicin. Three TACE/MMP inhibitors were evaluated in rat and human hepatocytes. Significantly higher PXR activation/CYP3A induction was observed in PXR/hepatocyte models, respectively, for (2R,3S) 3-(formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid [(1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl]amide (GW3333) compared with (2R,3S)-6,6,6-trifluoro-3-[formyl(hydroxy)amino]-2-isobutyl-N-[(1S,2R)-2-methoxy-1-[(1,3-thiazol-2-ylamino)carbonyl]propyl]hexanamide (GW6495) and (2R)-N-[(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]-propyl]-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-5-phenylpentanamide (GI4023). The CYP3A induction level achieved with GW3333 at a concentration of approximately 10 microM in human hepatocytes was comparable to that achieved with rifampicin at a concentration of 10 microM. The extent of rodent CYP3A induction caused by GW3333 was confirmed in vivo after daily oral administration for 14 days to rats. In conclusion, GW3333 is a potential inducer of CYP3A expression in vivo in humans, but other N-hydroxyformamides are less likely to induce CYP3A. 相似文献